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Background: Endometrial carcinoma is a common malignancy of female genital tract. Insulin-like growth factor is
known to elicit estrogen-induced mitogenic activity and anti-apoptotic effect in endometrial tissues.
Methods: The retrospective study investigated the expression of insulin-like growth factors, estrogen receptors and
their associations in endometrioid adenocarcinoma (EAC) from 80 EAC patients in immunohistochemistry, and
58 EAC patients and 42 control patients in quantitative RT-PCR. The Pearson correlation analysis was used to
analyze their correlations with clinic-pathological parameters.
Results: Our results showed that insulin-like growth factor-1 and insulin-like growth factor-2 mRNA levels were
higher in tumor tissues and tumor-adjacent tissues than those in control cells, and were inversely correlated with
the malignancy of the tumor with a positive correlation with ERα and ERβ expression. Insulin-like growth factor-1R
protein expression was correlated with clinical stage, and insulin-like growth factor-2R protein expression was
inversely correlated with histological grade.
Conclusions: Insulin-like growth factor system plays an important role in estrogen-induced endometrial
carcinogenesis, and overexpression of insulin-like growth factor-1R in the advanced endometrioid adenocarcinoma
is not estrogen-dependent.
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Endometrial carcinoma is the most common malignancy
of female genital tract in the United States [1]. Endome-
trioid adenocarcinoma (EAC) is the most common type
of endometrial carcinoma, accounting for more than
80% of the cases [2]. EAC is known to be estrogen-
related, and often occurs in postmenopausal women
with a history of excessive exposure of estrogen. Un-
opposed estrogen can produce endometrial hyperplasia,
and there is a strong association between endometrial
hyperplasia and EAC [3], suggesting that EAC represents
an estrogen-stimulated progression from endometrial* Correspondence: yuanjiao1965@126.com
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reproduction in any medium, provided the orhyperplasia to carcinoma. However, molecular mechan-
ism underlying the association between estrogen and
EAC has not been well established yet.
Estrogen exerts its biological effects through two dis-
tinct receptors, ERα and ERβ, which belong to the nu-
clear steroid superfamily. ERα is the predominant
estrogen receptor in human uterus, and is required for
endometrial proliferation in response to estrogen expos-
ure [4]. ERα is believed to be a prognostic factor for the
survival in endometrial cancers [5-7]. ERβ has been
found in both the normal and malignant endometrium,
and decreased expression of ERβ is associated with the
malignancy of the endometrial cancers [8-10]. However,
the association of ERα and ERβ expression with clinical
features of endometrioid adenocarcinoma has not been
well studied yet.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2407/12/262Insulin-like growth factor (IGF) is known to elicit
estrogen-induced mitogenic activity and anti-apoptotic
effect in endometrial tissues [11,12]. The IGF system
includes two growth factors (IGF-1 and IGF-2), two
receptors (IGF-1R and IGF-2R) and several binding pro-
teins (insulin-like growth factor binding proteins,
IGFBPs). Estrogens increase the expression of IGF-1 in
the uterus, and IGF-1 is required to mediate their mito-
genic effect on the edometrium [13,14]. In addition,
IGF-1 and IGF-2 has been reported to be involved in the
progression of endometrial adenocarcinoma [15]. The
availability and biological activities of IGFs are con-
trolled and modulated by IGFBPs. Progesterone has been
reported to increase IGFBP synthesis to antagonize
estrogen-induced cell proliferation [14,16]. Though
accumulated evidence shows that IGF family peptides
are linked with EAC, their exact roles in estrogen-
induced EAC remain unclear.
This study aimed to investigate the mRNA and protein
expression of IGF-1, IGF-2, IGF-1R, IGF-2R, and
IGFBP-3 as well as ERα and ERβ, to analyze their
correlation with surgico-pathological stage, histological
grade and depth of myometrial invasion, and to study
the relationship of IGF system with ERα and ERβ
expression in the EAC. Our study identified that IGF




The hysterectomy specimens from these patients were
collected between January, 2007 and July, 2010. This
study included tissue samples from 80 EAC patients for
immunohistochemistry, and tissue samples from 58 EAC
patients and 42 control patients for quantitative RT-
PCR. The study was in compliance with the Helsinki
Declaration, approved by review board, of Nanjing Uni-
versity School of Medicine and all subjects were gave
their informed consent. The quantitative PCR used spe-
cimens from 58 patients with EAC and 42 control
patients with no endometrial diseases. The median age
of the patients with EAC was 61 years (range 33-
79 years). The cancers were classified according to
recommendations of International Federation of
Gynecology and Obstetrics (FIGO) in 2009. The
surgico-pathologic staging of the cancers was as follows:
stage I (n = 33), stage II (n = 15), stage III (n = 10), and
stage IV (n = 0). The pathologic grading of the cancers
was as follows: G1 (n = 14), G2 (n = 31), and G3 (n = 13).
The endometrium outside the cancer loci was selected
as tumor adjacent group, including 24 cases with atyp-
ical hyperplasia, 4 cases with complex hyperplasia, and 3
cases with proliferative phase of endometrium. The
tumor samples and their clear surgical margin sampleswere removed during surgery, and were examined by a
pathologist. The tumor-adjacent samples were selected
from the clear surgical margin, which was defined as the
1 cm2 areas of tissues outside the tumor loci without
any neoplasmatic texture histologically. Each diagnosis
was confirmed by pathological staining, and all patients
did not undergo radiation therapy, chemotherapy and
hormonal therapy. The control endometria were col-
lected from 42 patients (median age, 58 years) who
underwent hysterectomy, and were confirmed to be nor-
mal by pathologic examination. The control group
included 24 cases with the proliferative phase of endo-
metrium and 18 cases with the secretory phase of endo-
metrium. Immunohistochemistry experiments used
specimens from 80 patients with EAC. The median age
of the patients with EAC was 65 years (range 33-
84 years). The surgico-pathologic staging of the cancers
was as follows: stage I (n = 45), stage II (n = 19), stage III
(n = 16), and stage IV (n = 0). The pathologic grading of
the cancers was as follows: G1 (n = 21), G2 (n = 45),
and G3 (n = 14). The control group included 22 cases
with normal endometrium, and 33 cases with atypical
hyperplasia.
RNA isolation and quantitative real-time RT-PCR
Total RNA was isolated from endometrial tissues from
58 patients with EAC and 42 control patients by using
Trizol reagent (Invitrogen, USA) according to manufac-
turer’s protocol. RNA was reverse transcribed into com-
plementary DNA using reverse transcription system.
Quantitative real time RT-PCR was performed with pri-
mers and TaqMan probes listed in Table 1.
Immunohistochemistry
Tissue sections (4 μM thick) were obtained from
formalin-fixed and paraffin-embedded tissue blocks from
80 hysterectomy specimens. The tissue sections were
immunohistochemically stained for IGF-1R, IGF-2R,
ERα and ERβ, using EnVision method as previously
described. Briefly, sections were washed in xylene to re-
move the paraffin, rehydrated with serial dilutions of al-
cohol, followed by a wash in PBS solution. The samples
were then incubated in primary antibodies against IGF-
1R (polyclonal rabbit anti-human IGF-1R, 1:50 dilution,
Wuhan Boster. Bio-engineering Co., Ltd., Wuhan,
China), IGF-2R (polyclonal rabbit anti-human IGF-2R,
1:50 dilution, Wuhan Boster. Bio-engineering Co., Ltd.,
Wuhan, China), ERα (monoclonal rabbit anti-human
ERα, 1:50 dilution, Fujian Maixin. Biological Technolog,
Fujian, China) and ERβ (monoclonal rabbit anti-human
ERβ, 1:50 dilution, Fujian Maixin. Biological Technolog,
Fujian, China) overnight at 4 °C. After the primary anti-
body was washed off, the components of the Envision-
plus (DAKO) detection system were applied, and
Table 1 The primers and TaqMan probes of IGF, ER genes used for RT-PCR
Genes (Accession No.) Primers and probe size Annealing temperature
IGF-1 (NM_000618) Forward: 5-AGCTGTGATCTAAGGAGGCTGG-3’ 143 bp 57 °C
Reverse: 5’-GCACTCCCTCTACTTGCGTTCTT-3’
Probe: 5’-(FAM)-TCAGCTCGCTCTGTCCGTGCCC-3’(TAMRA)
IGF-1R (NM_000875) Forward: 5’-CTTGTACATTCGCACCAATGCT-3’ 83 bp 59 °C
Reverse: 5’-CGATTAACTGAGAAGAGGAGTTCGA-3’
Probe: 5’-CTTCCATTCCCTTGGACGTTCTTTCAGC-3’
IGF-2 (NM_000612) Forward: 5’-AGGAGCTCGAGGCGTTCA-3’ 65 bp 55 °C
Reverse: 5’-GTCTTGGGTGGGTAGAGCATC-3’
Probe: 5’-AGGCCAAACGTCACCGTCCCC-3’
IGF-2R (NM_000876) Forward: 5’-GCGGCACACCCTATAACAATG-3’ 74 bp 59 °C
Reverse: 5’-CGCGTCTCGATCACAGAGAA-3’
Probe: 5’-AAGACACACACCGAGAGCTACGCTCATCA-3’
IGFBP-3 (NM_000596) Forward: 5’-CAGGAGACATCAGGAGAAGAAATTT-3’ 117 bp 59 °C
Reverse: 5’-TCCCGCCTCTCCATCCAT-3’
Probe: 5’-TTACCTGCCAAACTGCAACAAGAATGGATT-3’
ERα (NM_000125) Forward: 5’-AGAGGGCATGGTGGAGATCTT-3’ 83 bp 59 °C
Reverse: 5’-CAAACTCCTCTCCCTGCAGATT-3’
Probe: 5’-(FAM)TGATGACACTGCCACTCCTGAGGCA-3’(TAMRA)
ERβ (NM_001437) Forward: 5’-GACCACAAGCCCAAATGTGTT-3’ 69 bp 59 °C
Reverse: 5’-AACTGGCGATGGACCACTAAA-3’
Probe: 5’-(FAM)TGGCCAACACCTGGGCACCTTT-3’(TAMRA)
GAPDH (NM_002046) Forward: 5’-CCAGGTGGTCTCCTCTGACTT-3’ 130 bp 59 °C
Reverse: 5’-GTTGCTGTAGCCAAATTCGTTGT-3’
Probe: 5’-(FAM)AACAGCGACACCCACTCCTCCACC-3’(TAMRA)
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sue sections from known breast cancer were used as
positive control, and sections in which primary anti-
bodies were omitted were used as negative control.
The immunostaining was examined under the light
microscope by two observers blind to the experimental
conditions, using an immunohistochemical scoring sys-
tem according to the percentage of stained cells and the
intensity of the immunoreactivity [17]. The agreement
on the scores between the two observers was nearly
100%. In cases in which the observers disagreed in the
score, the immunohistochemical scoring was repeated
by both observers until the same score was achieved.
The percentage of stained cells was scored as follows: 0
for no stained cells, 1 for <10% of stained cells, 2 forTable 2 The mRNA levels of IGF-1, IGF-1R, IGF-2, IGF-2R, IGFB
groups
groups n IGF-1 IGF-1R IGF-2
Control 42 0.58 ± 0.30 0.54 ± 0.32 0.33 ± 0.19
EAC 58 1.19 ± 00.79* 6.23 ± 3.98* 2.44 ± 2.32*
Tumor-adjacent 31 2.66 ± 01.73# 35.34 ± 22.02# 8.59 ± 7.13#
*p < 0.05 vs control,#P< 0.05 vs EAC (endometrioid adenocarcinoma) by one-way AN10% to 50% of stained cells, and 3 for >50% of stained
cells. The intensity of immunoreactivity was scored as
follows: 0 for no staining, 1 for weak staining, 2 for
moderate staining, and 3 for strong staining. The final
immunoreactive score was determined by the sum of
both the intensity score and the score for the percentage
of positively stained cells. The negative, positive and
strong positive immunoreactivity is defined by a final
score of ≤ 1, 2-3, and ≥ 4, respectively.
Statistical analysis
Statistical analyses were performed using SPSS 13.0. The
values were presented as mean and standard deviation.
If equal variances were achieved, one-way analysis of
variance (ANOVA) was used for comparison of theP-3, ERα and ERβ in EAC, tumor-adjacent, and control
IGF-2R IGFBP-3 ERα ERβ
0.04 ± 0.03 4.58 ± 3.35 16.24 ± 10.10 50.10 ± 21.60
4.32 ± 2.98* 14.47 ± 12.31* 10.67 ± 7.63 31.44 ± 25.22
0.39 ± 0.36# 8.28 ± 4.57# 45.54 ± 33.58# 529.62± 269.7#
OVA.
Figure 1 Expression of ERα using immunohistochemical analysis in normal endometrium (A) (×200), atypical hyperplasic endometrium
(B) (×400), endometrial adenocarcinoma with high differentiation (C) (×200), and endometrial adenocarcinoma with low differentiation
(D) (×100).
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http://www.biomedcentral.com/1471-2407/12/262difference in the means among cancer group, tumor-
adjacent group and control group using LSD (least sig-
nificant difference) method. If equal variances were not
achieved, Welch approximate analysis of variance wasFigure 2 Expression of ERβ using immunohistochemical analysis in no
(B) (×200), endometrial adenocarcinoma with high differentiation (C)
(D) (×200).performed to analyze the differences among groups
using Tamhan’s T2 method. Categorical data were com-
pared with chi square. The Pearson correlation analysis
was applied to assess the relationship between IGFs andrmal endometrium (A) (×200), atypical hyperplasic endometrium
(×200), and endometrial adenocarcinoma with low differentiation
Figure 3 Expression of IGF-1R (A, B) and IGF-2R (C, D) using immunohistochemical analysis in endometrial adenocarcinoma with high
differentiation (A) (×400), endometrial adenocarcinoma with low differentiation (B) (×400), endometrial adenocarcinoma with
moderate differentiation (C) (×400), and endometrial adenocarcinoma with low differentiation (D) (×200).
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of EAC. Probability values less than 0.05 were consid-
ered statistically significant.
Results
Expression of IGFs and ERs in endometrioid
adenocarcinoma at mRNA and protein levels
We tested the expression of IGF-1, IGF-1R, IGF-2, IGF-
2R, IGFBP-3, ERα and ERβ mRNA on 58 tumor tissue
samples and 31 tumor-adjacent endometrial tissue sam-
ples from patients with EAC and 42 normal endometrial
tissue samples, using RT-PCR. The mRNA level of IGF-
1, IGF-1R, IGF-2, IGF-2R, and IGFBP-3 was significantly
higher in tumor and tumor-adjacent endometrium than
that in control endometrium (p < 0.05, Table 2). The
tumor endometrium expressed significantly lower levels
of IGF-1, IGF-1R, and IGF-2, and significantly higher
levels of IGF-2R and IGFBP-3, compared with tumor-
adjacent endometrium (p < 0.05, Table 2). In addition,
the mRNA level of ERα and ERβ was not significantly
different between the tumor group and the control
group (p > 0.05). The tumor-adjacent endometrium
expressed higher levels of ERα and ERβ compared with
both tumor endometrium and normal endometrium
(p < 0.05, Table 2).
We then detected the protein expression of IGF-1R,
IGF-2R, ERα and ERβ on 80 tumor samples from
patients with EAC, 33 samples from patients with atyp-
ical hyperplasia, 22 samples from control patients, usingimmunohistochemistry (Figures 1, 2, 3). Nuclear immu-
noreactivity was observed for both ERα and ERβ with no
cytoplasmic immunoreactivity (Figures 1, 2). ERα immu-
noreactivity was strongly positive in normal endomet-
rium and atypical hyperplasic endometrium with a
positive staining rate ranging from 93.9% to 100%, while
73.8% of endometrioid adenocarcinoma exhibited the
positive immunoreactivity to ERα with a strong positive
staining rate of 12.5% (Table 3). In contrast, ERβ immu-
noreactivity was weakest in normal endometrium and
the strongest in EAC. The strong positive staining rate
was 13.6%, 25.5%, and 93.8% in normal endometrium,
atypical hyperplasic endometrium and EAC, respectively
(Table 3). For IGF-1R, the highest expression rate was
seen in EAC, and the lowest expression rate was found
in normal endometrium. The strong positive staining
rates were 5%, 27.3%, and 40% in normal endometrium,
atypical hyperplasic endometrium and EAC, respectively
(Table 3). However, IGF-2R immunoreactivity occurred
more frequently in atypical hyperplasic endometrium,
and less frequently in EAC. The strong positive staining
rates were 45.5%, 75.8%, and 12.5% in normal endomet-
rium, atypical hyperplasic endometrium and EAC, re-
spectively (Table 3).
Association of IGF and ER expression with clinico-
pathological features of EAC
We investigated the association of IGF-1, IGF-1R, IGF-
2, IGF-2R, IGFBP-3, ERα and ERβ mRNA expression
Table 3 The immunostaining of IGF-1R, IGF-2R, ERα and ERβ in EAC, atypical hyperplasia, and control groups
groups n ERα ERβ IGF-1R IGF-2R
Positive (%) Strong positive(%) Positive (%) Strong positive(%) Positive (%) Strong positive(%) Positive (%) Strong positive(%)
Control 22 22(100) 22(100) 13(59.09) 3(13.64) 14(63.64) 1(5.0) 16(72.72) 10(45.45)
Atypical hyperplasia 33 32(95.65) 31(93.93) 26(78.79) 15(45.45) 25(75.76) 9(27.27) 27(81.82) 25(75.75)
EAC 80 59(73.75) 10(12.5) 78(97.5) 75(93.75) 72(90.0) 32(40.0) 15(18.75) 10(12.50)
x2 18.961 92.295 23.444 62.864 8.953 10.421 47.424 43.807


















Table 4 The relationship between the IGF and ER mRNA expression and clinico-pathological features of endometrioid
adenocarcinoma
Clinical pathology (n) IGF-1 IGF-2 IGF-1R IGF-2R IGFBP-3 ERα ERβ
Surgico-pathological stage I(33) 1.70 ± 0.73▼ 3.28 ± 2.17▼ 1.62 ± 0.86 4.97 ± 2.77 14.91 ± 13.03 16.57 ± 4.1▼ 42.04 ± 23.28
II(15) 0.58 ± 0.09* 1.73 ± 2.47 1.84 ± 0.96 4.70 ± 2.96* 13.25 ± 13.32 4.33 ± 2.39* 25.70 ± 24.47*
III(10) 0.44 ± 0.02# 0.72 ± 1.31# 1.50 ± 0.79 1.60 ± 2.50# 14.83 ± 16.79 0.72 ± 0.33# 5.07 ± 2.11#
Histological grade G1(14) 1.44 ± 0.24 3.25 ± 2.27 1.53 ± 1.92 4.75 ± 3.01 16.22 ± 14.47 16.85 ± 4.37▲ 41.93 ± 26.78
G2(31) 1.39 ± 0.95$ 2.53 ± 2.38$ 1.32 ± 0.99 4.92 ± 2.63$ 11.78 ± 11.27 11.70 ± 6.94$ 35.08 ± 23.96$
G2(13) 0.47 ± 0.07& 1.34 ± 2.02& 1.66 ± 0.84 2.42 ± 3.27& 18.99 ± 16.87 1.55 ± 1.79& 11.47 ± 16.42&
Depth of myometrial invasion ≤ 50%(39) 1.47 ± 0.79 3.14 ± 2.27 1.55 ± 0.90 5.26 ± 2.68 15.82 ± 12.78 14.28 ± 5.64 41.48 ± 24.10
>50%(19) 0.63 ± 0.46@ 0.98 ± 1.76@ 1.15 ± 0.78 2.39 ± 2.75@ 11.69 ± 15.01 3.26 ± 5.86@ 10.83 ± 12.55@
▼p< 0.05 stage I vs stage II;*P< 0.05 stage II vs stage III; #P< 0.05 stage I vs stage III;▲P< 0.05 G1 vs G2;$P< 0.05 G2 vs G3;&P< 0.05 G1 vs G3;@P< 0.05 vs ≤50% of
mymetrial invasion by one-way ANOVA.
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http://www.biomedcentral.com/1471-2407/12/262with surgico-pathological stage in EAC (Table 4). Out of
58 cases evaluated, there were 33 stage I, 15 stage II, and
10 stage III tumors. The expression of IGF-1, IGF-2 and
IGF-2R was decreased with the increased stage of
tumors (P < 0.05), though no significant difference was
found between stage II and stage III tumors in IGF-2 ex-
pression, and between stage I and stage II tumors in
IGF-2R expression. There was no significant change in
IGF-1R and IGFBP-3 expression with the stage of the
tumors. Decreased expression of ERα and ERβ was
found with the increased stage of tumors (P < 0.05).
We examined the association of IGF-1, IGF-1R, IGF-2,
IGF-2R, IGFBP-3, ERα and ERβ mRNA expression with
histological grade in EAC (Table 4). The histological
grade of the 58 cases was classified into 3 groups: well
differentiated (G1, n = 14), moderate-differentiated (G2,
n = 31) and poor-differentiated (G3, n = 13). The
mRNA expression of IGF-1, IGF-2, and IGF-2R was
decreased with the lack of differentiation with a sig-
nificant difference between G1 and G3 groups and be-
tween G2 and G3 groups. No significant change was
identified in the mRNA expression of IGF-1R and
IGFBP-3 among G1, G2 and G3 groups. The mRNA
expression of ERα and ERβ was decreased with the
lack of differentiation with a significant difference
among G1, G2 and G3 groups.
We also tested the association of IGF-1, IGF-1R, IGF-
2, IGF-2R, IGFBP-3, ERα and ERβ mRNA expression
with the depth of myometrial invasion in EAC (Table 4).
Of the 58 cases, superficial myometrial invasion (≤ 50%
of myometrium) was present in 39 cases, and deep myo-
mytrial invasion (> 50% of myometrium) was present in
19 cases. The mRNA expression of IGF-1, IGF-2 and
IGF-2R, but not IGF-1R and IGFBP-3, was decreased
with the increased depth of myometrial invasion. The
ERα and ERβ mRNA expression was significantly lower
in the EAC with deep myometrial invasion than that
with superficial myometrial invasion.We investigated the association of IGF-1R, IGF-2R,
ERα and ERβ protein expression with the surgico-
pathological stage, histological grade, and depth of myo-
metrial invasion in the EAC (Table 5). The percentage of
IGF-1R-positive staining was increased, and the percent-
age of IGF-2R-positive staining was decreased with the
increased surgico-pathological stage, histological grade,
and depth of myometrial invasion. In addition,
decreased ERα-positive immunostaining was observed
with the increased surgico-pathological stage, histo-
logical grade, and depth of myometrial invasion. How-
ever, though strong positive staining for ERβ in 93.75%
of EAC samples, ERβ-positive immunostaining exhib-
ited no significant difference in the surgico-
pathological stage, histological grade, and depth of
myometrial invasion.
Correlation analysis of IGF and ER expression with
clinico-pathological features of EAC
A strong inverse correlation of IGF-1 and IGF-2 mRNA
expression, a weak inverse correlation of IGF-2R mRNA
expression, and no correlation of IGF-1R and IGFBP-3
mRNA expression were found with the surgico-
pathological stage, histological grade, and depth of myo-
metrial invasion (Table 6). Similar to IGF-1 and IGF-2, a
strong inverse correlation of ERα and ERβ was observed
with the surgico-pathological stage, histological grade,
and depth of myometrial invasion (Table 6).
IGF-1R protein expression was correlated with the
surgico-pathological stage, histological grade, and depth
of myometrial invasion, and IGF-2R protein expression
was inversely correlated with histological grade, but
not with the surgico-pathological stage and depth of
myometrial invasion (Table 7). In addition, ERα protein
expression was inversely correlated with surgico-
pathological stage and histological grade, but ERβ pro-
tein expression exhibited no correlation with all the
studied parameters (Table 7).
Table 5 The relationship between the IGF-1R, IGF2R, ERα and ERβ protein expression and clinico-pathological features of endometrioid adenocarcinoma
Clinical pathology n ERα ERβ IGF-1R IGF-2R
Positive (%) Strong positive(%) Positive (%) Strong positive(%) Positive (%) Strong positive(%) Positive (%) Strong positive(%)
Surgico-pathological stage I 45 40(88.9) 19(42.2) 45(100) 43(95.6) 39(86.7) 7(15.6) 11(24.4) 5(11.1)
II 19 14(73.7) 0(0) 18(94.7) 13(68.4) 17(89.5) 10(52.6) 2(10.5) 0(0)
III 16 5(31.3) 0(0) 15(93.8) 16(100) 16(100) 15(93.8) 2(12.5) 0(0)
x2 18.935 7.334 3.388 3.225 3.886 31.727 2.316 2.544
P value 0.000 0.013 0.184 0.237 0.143 0.000 0.314 0.291
Histological grade G1 21 21(100) 9(42.8) 21(100) 21(100) 13(61.9) 4(19.1) 10(47.6) 5(23.8)
G2 45 33(73.3) 10(22.2) 45(100) 38(84.4) 45(100) 15(33.3) 4(19.1) 0(0)
G3 14 5(35.7) 0(0) 13(92.9) 13(92.9) 14(100) 13(92.9) 1(7.1) 0(0)
x2 21.663 2.543 3.547 3.844 24.103 20.972 13.974 2.689
P value 0.000 0.447 0.170 0.163 0.000 0.000 0.001 0.304
Depth of myometrial invasion ≤1/2 58 53(91.4) 13(22.47) 56(96.6) 51(87.9) 50(86.2) 14(24.1) 11(19.0) 5(8.6)
>1/2 22 6(27.3) 6(27.3) 22(100) 21(95.5) 22(100) 18(81.8) 4(18.2) 0(0)
x2 33.853 3.345 0.006 0.102 2.013 22.111 0.000 1.015


















Table 6 Correlation analysis of IGF and ER mRNA









IGF-1 -0.8909* -0.6434* -0.6704*
IGF-2 -0.5867* -0.3907* -0.5826*
IGF-1R -0.0901 0.1587 0.0675
IGF-2R -0.3519* -0.2842* -0.4663*
IGFBP-3 -0.0549 0.1012 -0.1920
ERα -0.8807* -0.6906* -0.6803*
ERβ -0.6384* -0.4958* -0.6616*
*P< 0.05 using Pearson correlation analysis with linear regression.
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expression
We further study the correlation of IGF-1, IGF-1R, IGF-
2, IGF-2R, and IGFBP-3 mRNA expression with ERα
and ERβ mRNA expression in tumor, tumor-adjacent
and control endometria (Table 8). In the control group,
there was no correlation of IGF-1, IGF-1R, IGF-2, IGF-
2R, and IGFBP-3 expression with ERα and ERβ expres-
sion. In the tumor group, IGF-1 and IGF-2 levels were
strongly correlated with ERα expression (r = 0.6439 for
IGF-1, r = 0.5228 for IGF-2), and were weakly correlated
with ERβ expression (r = 0.4155 for IGF-1, r = 0.3555 for
IGF-2). IGF-2R expression was weakly correlated with
both ERα (r = 0.2970) and ERβ (r = 0.2756) expression.
No correlations of either ERα or ERβ expression were
found with IGF-1R and IGFBP-3 expressions. In tumor-
adjacent group, the IGF-2 level was strongly correlated
with both ERα (r = 0.8502) and ERβ (r = 0.9327) expres-
sions. Strong correlation of IGF-1R expression was
observed with ERα expression (r = 0.5545), but not with
ERβ expression (r = -0.0399). There were no correlations
of IGF-1, IGF-2R and IGFBP-3 with either ERα or ERβ
expressions.Discussion
IGF family including IGF-1, IGF-2, their receptor IGF-
1R and IGF-2R, and IGFBPs, regulates cell proliferation,Table 7 Correlation analysis of IGF-1R, IGF-2R, and ERα










ERα -O.468* -0.386* -0.238*
ERβ 0.321 0.209 0.096
IGF-1R 0.616* 0.628* 0.546*
IGF-2R -0.134 -0.379* -0.104
*P< 0.05 using Pearson correlation analysis with linear regression.metabolism and differentiation in normal cells, and plays
an important role in growth and progression of many
tumors [18]. In endometrium, IGF family is believed to
function as a mediator of estrogen actions through para-
crine/autocrine mechanisms, and is associated with
estrogen-induced endometrial carcinogenesis [11-15].
However, the function of IGF system in the EAC
remains unclear. Here we investigate the expression of
IGF family using RT-PCR and immunohistochemistry,
and analyze its correlations with clinicopathological fea-
tures and ER expression in the EAC. We find that ex-
pression of IGF-1, IGF-2 and IGF-2R mRNA is inversely
correlated with the surgico-pathological stage, histo-
logical grade, and depth of myometrial invasion, and is
correlated with ERα and ERβ expression in EAC. IGF-1R
protein expression is correlated with surgico-
pathological stage, histological grade, and depth of myo-
metrial invasion, and IGF-2R protein expression is in-
versely correlated with histological grade, but not with
the surgico-pathological stage and depth of myometrial
invasion. In addition, we also find that the expression of
IGF-1, IGF-2, and IGF-2R, but not IGF-1R, is correlated
with ERα and ERβ expression. Since ERα and ERβ ex-
pression is associated with EAC carcinogenesis, our
results suggest that IGF-1, IGF-2 and IGF-2R may play
an important role in estrogen-induced endometrial car-
cinogenesis, and overexpression of IGF-1R in the EAC is
not estrogen-dependent.
Estrogens, acting through ERα and ERβ, play a key
role in development and progression of EAC. High levels
of ERα are believed to be favorable for prognosis and
treatment of EAC [5-7]. Consistent with this idea, we
find that the normal endometrium expresses higher
levels of ERα than the EAC, and decreased expression of
ERα is correlated with the malignancy of the tumor.
However, the expression of ERβ protein exhibits no cor-
relation with the malignancy of EAC. Though excessive
estrogen has been associated with the carcinogenesis of
EAC, the mechanisms underlying the estrogen-mediated
carcinogenesis remain unclear. Growing evidence shows
the involvement of IGF system in the carcinogenesis andTable 8 The analysis of the correlation between the
mRNA expression of IGFs with ER subtypes in three
groups
groups IGF-1 IGF-1R IGF-2 IGF-2R IGFBP-3
control ERα 0.2151 -0.1216 -0.1543 0.1938 -0.1150
ERβ 0.1881 0.0719 -0.1295 -0.1145 -0.2147
EAC ERα 0.6439* 0.2537 0.5228* 0.2970* 0.1519
ERβ 0.4155* 0.1429 0.3555* 0.2756* 0.0583
Tumor-adjeacent ERα 0.3009 0.5545* 0.8502* -0.0699 -0.2465
ERβ 0.0925 -0.0399 0.9327* 0.2615 -0.2710
*P< 0.05 using Pearson correlation analysis with linear regression.
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women has been associated with the increased risk of
EAC [19,20]. IGF-1 and IGF-2 has been reported to be
involved in the progression of EAC [15]. The involve-
ment of both estrogen and IGF signaling pathway in the
EAC suggests that the interaction of estrogen with IGF
signaling pathways may be important in the pathogen-
esis of EAC similar to that in the breast cancer [21]. This
idea is supported by the reports that estrogen stimulates
the expression of IGF-1, and IGF-1 is required to medi-
ate estrogen action in the endometrium [13,14,22].
In our study, the IGF-1 and IGF-2 mRNA levels are
much higher in tumor cells and tumor-adjacent cells
than those in control tissues, suggesting that IGF-1
and IGF-2 may be a critical mediator for transforming
from normal cell into tumor cells. This finding agrees
with reports that IGF-1 and IGF-2 elicit tumorigen-
esis through autocrine mechanism [11,12]. However, a
strong inverse correlation of IGF-1 and IGF-2 expres-
sion is found with the surgico-pathological stage,
histological grade, and depth of myometrial invasion
of EAC, suggesting that IGF-1 and IGF-2 function
through autocrine mechanism may not be critical in
the development of the malignancy of EAC. Our
study can not exclude the possibility that IGF-1 and
IGF-2 play a critical role in the development of EAC,
since we did not test the plasma levels of IGFs which
have been associated with EAC [19,20]. In addition,
the tumor-adjacent endometrium, including mostly
atypical hyperplasia, expresses higher level of IGF-1
and IGF-2 mRNA than EAC, further suggesting that
IGF-1 and IGF-2 may play a role in the transform-
ation to atypical hyperplasia, but the transformation
from atypical hyperplasia into tumor may be IGF-in-
dependent. This idea is supported by the report that mel-
anoma is sensitive to IGF-1 at the early stage, but
insensitive to IGF-1 at the late stage of development [23].
In addition, the finding that IGF-1 and IGF-2 expression
is correlated with the expression of both estrogen recep-
tors is consistent with the idea that IGF expression is
regulated by estrogen, and IGF may mediate estrogen-
induced cell proliferation in the endometrium [13].
Effects of IGF-1 and IGF-2 are mediated through two
receptors: IGF-1R and IGF-2R. Both IGF-1 and IGF-2
interact with IGF-1R, and IGF-2 also acts on IGF-2R.
IGF-1R is regarded as a mediator for cancer cell prolif-
eration, differentiation, growth and progression [18,24].
In agreement with the reports that overexpression of
IGF-1R occurs in a variety of human cancer [24,25], we
identify that IGF-1R protein expression is highest in the
EAC, and is correlated with the surgico-pathological
stage, histological grade, and depth of myometrial inva-
sion of EAC. The percentage of IGF-1R-possitive cells is
increased with the increased surgico-pathological stage,histological grade, and depth of myometrial invasion.
However, since ERα protein expression is inversely cor-
related with the malignancy of EAC, no correlation of
IGF-1R expression is observed with either ERα or ERβ
expression, suggesting that overexpression of IGF-1R in
the advanced EAC is not estrogen-dependent. In con-
trast, IGF-2R, structurally and functionally different
from IGF-1R, is expressed at a low level in the EAC, and
is reversely correlated with the malignancy of the EAC.
This agrees with the fact that IGF-2R functions as a
tumor suppressor to sequester IGF-2 from circulation
[26,27]. In addition, the IGF-2R expression was signifi-
cantly correlated with both ERα and ERβ expression in
the EAC, suggesting that IGF-2R expression is estrogen-
dependent.
The molecular mechanisms of estrogen-induced ex-
pression of IGF1, IGF2 and IGF-1R and IGF-2R are
largely unknown. It has been reported that estrogen
treatment increases IGF1 mRNA expression in EAC
cells [28], possibly through regulation of IGF-1 gene pro-
moter and a transcription factor C/EBPδ [29]. It is likely
that estrogen can induce IGF-1, IGF-2, and their recep-
tors through modulating their gene promoters and tran-
scription factors. In this study, we find that the
expression of IGF-1, IGF-2, and IGF-2R, is correlated
with ERα and ERβ expression, suggesting that the ex-
pression of IGF-1 and IGF-2 and IGF-2R may be regu-
lated by estrogen, and thus may play an important role
in estrogen-induced endometrial carcinogenesis. Overex-
pression of IGF-1R in the EAC is not correlated with
ERα and ERβ expression in the EAC, suggesting that
regulation of IGF-1R may be not estrogen-dependent.
The mechanism underlying IGF-1R expression is un-
clear. However, it is reported that overexpression of
IGF-1R in a mouse model of transgenic expression of a
constitutively active IGF-1R induces tumor development
without the stimulation by any exogenous IGF-1R ago-
nists or estrogen. An estrogen-independent mechanism
underlying the overexpression of IGF-1R identified in
this study remains to be further investigated.
The biological function of IGF peptides are also modu-
lated by a family of IGF binding proteins, which are
found in the circulation and in the extracellular fluids.
IGFBP-3 is the predominant IGFBP in the plasma, and
IGFBP-3 has been associated with endometrial carcin-
oma in postmenopausal women [30]. In addition, genetic
variants in IGFBP-3, not IGFBP-1 is associated with the
risk of endometrial carcinoma [31]. However, the expres-
sion of IGFBP-3 in the EAC and its association with the
malignancy of the cancer and the expression of estrogen
receptors remain unclear. Our study shows that no cor-
relation of IGFBPs expression is found with the malig-
nancy of EAC and the expression of estrogen receptors,
suggesting that the IGFBP-3 is not critical in the
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EAC is not estrogen-mediated.
There are some limitations to this study. First, this
study included tissue samples from 80 EAC patients, but
we only included tissue samples 58 EAC patients for
quantitative RT-PCR. These samples used for RT-PCR
were examined by a pathologist after the tumor was
removed during surgery, and those samples without the
pathologist’s examination were excluded. Though the
sample size is large enough to compare the difference in
the mRNA expression between the EAC and control, a
large size of samples may be better to fully examine the
mRNA expression of IGFs in the EAC. Second, our con-
trol samples included endometrial tissues in the prolif-
erative phase and in the secretory phase. Due to the
limited samples in the control study, we only tested the
24 control tissues in the proliferative phase and the 18
control tissues in the secretory phase. We do not find
any significant difference in IGFs expression between tis-
sues in the proliferative phase and in the secretory phase
(data not shown), though the gene expression of IGFs in
the proliferative and the secretary phase may be chan-
ged. A significant difference in the expression of IGFs
between the control and the EAC is found in our study,
suggesting that the sample size and the control samples
with different endometrial phases do not affect our
results greatly. Third, we did not test the plasma levels
of IGFs which are reported to be associated with EAC.
The expression of IGFs in the tumor reflects the synthe-
sis and release of IGFs from the tumor, and the plasma
levels of IGFs are affected by the synthesis and release of
IGFs from many organs, especially the liver. It is worthy
to investigate the correlation of plasma IGFs with the
surgico-pathological stage, histological grade, and depth
of myometrial invasion of EAC in the future.
Conclusion
The present study has indicated that insulin-like growth
factor system plays an important role in estrogen-
induced endometrial carcinogenesis, and overexpression
of insulin-like growth factor-1R in the advanced endo-
metrioid adenocarcinoma is not estrogen-dependent.
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